Efficacy of two interventions on the discontinuation of benzodiazepines in long-term users: 36-month follow-up of a cluster randomised trial in primary care

• Published in: British journal of general practice 2016-02, Vol.66 (643), p.e85-e91
• Main Authors: Vicens, Caterina, Sempere, Ermengol, Bejarano, Ferrán, Socias, Isabel, Mateu, Catalina, Fiol, Francisca, Palop, Vicente, Mengual, Marta, Folch, Silvia, Lera, Guillem, Basora, Josep, Leiva, Alfonso
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders - drug therapy; Benzodiazepines - administration & dosage; Depressive Disorder - drug therapy; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Education as Topic; Primary Health Care - methods; Quality of Life; Retrospective Studies; Substance Withdrawal Syndrome - etiology; Substance Withdrawal Syndrome - therapy; Time Factors; Withholding Treatment; Young Adult
• ISSN: 0960-1643; 1478-5242
• DOI: 10.3399/bjgp16X683485

Primary care interventions that promote cessation of benzodiazepine (BZD) use in long-term users are effective at 1 year, but their efficacy at 3 years is uncertain. To assess the 3-year efficacy of two primary care interventions delivered by GPs on cessation of BZD use in long-term users. Multicentre, three-arm, cluster randomised, controlled trial, with random allocation at the GP level. Seventy-five GPs and 532 patients were randomly allocated to three groups: usual care (control), structured intervention with stepped-dose reduction and follow-up visits (SIF), or structured intervention with written stepped-dose reduction (SIW). The primary outcome was BZD use at 36 months. At 36 months, 66/168 patients (39.2%) in the SIW group, 79/191 patients (41.3%) in the SIF group, and 45/173 patients (26.0%) in the control group had discontinued BZD use. The relative risks (RR) adjusted by cluster were 1.51 (95% CI = 1.10 to 2.05; P = 0.009) in the SIW group and 1.59 (95% CI = 1.15 to 2.19; P = 0.005) in the SIF group. A total of 131/188 patients (69.7%) who successfully discontinued BZD use at 12 months remained abstinent at 36 months. The groups showed no significant differences in anxiety, depression, or sleep dissatisfaction at 36 months. The interventions were effective on cessation of BZD use; most patients who discontinued at 12 months remained abstinent at 3 years. Discontinuation of BZD use did not have a significant effect on anxiety, depression, or sleep quality.